Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in ...
A recent study reveals that bacteria residing within colorectal tumors form distinct ecosystems closely linked to disease ...
In this interview, we spoke with Associate Professor Diana Mechtcheriakova about how lymphoid structures and germinal centers are unlocking new prognostic insights into colorectal cancer, and with ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification ...
Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback